vs

Side-by-side financial comparison of Globalstar, Inc. (GSAT) and Health Catalyst, Inc. (HCAT). Click either name above to swap in a different company.

Health Catalyst, Inc. is the larger business by last-quarter revenue ($74.7M vs $72.0M, roughly 1.0× Globalstar, Inc.). Globalstar, Inc. runs the higher net margin — -16.1% vs -121.9%, a 105.7% gap on every dollar of revenue. On growth, Globalstar, Inc. posted the faster year-over-year revenue change (17.6% vs -6.2%). Over the past eight quarters, Globalstar, Inc.'s revenue compounded faster (12.9% CAGR vs -0.0%).

Globalstar, Inc. is an American telecommunications company that operates a satellite constellation in low Earth orbit (LEO) for satellite phone, low-speed data transmission and Earth observation. The Globalstar second-generation constellation consists of 25 satellites.

Catalyst Pharmaceuticals, Inc. is a biopharmaceutical company based in Coral Gables, Florida, United States. The company develops medicines for rare diseases, including the phosphate salt of amifampridine for the treatment of Lambert–Eaton myasthenic syndrome (LEMS). The drug is referred to under the trade name Firdapse, which was approved by the FDA for approved use in children 6 years and older with LEMS in addition to the prior approval for use in adults with LEMS on November 28, 2018. Fir...

GSAT vs HCAT — Head-to-Head

Bigger by revenue
HCAT
HCAT
1.0× larger
HCAT
$74.7M
$72.0M
GSAT
Growing faster (revenue YoY)
GSAT
GSAT
+23.8% gap
GSAT
17.6%
-6.2%
HCAT
Higher net margin
GSAT
GSAT
105.7% more per $
GSAT
-16.1%
-121.9%
HCAT
Faster 2-yr revenue CAGR
GSAT
GSAT
Annualised
GSAT
12.9%
-0.0%
HCAT

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
GSAT
GSAT
HCAT
HCAT
Revenue
$72.0M
$74.7M
Net Profit
$-11.6M
$-91.0M
Gross Margin
Operating Margin
-0.5%
-115.3%
Net Margin
-16.1%
-121.9%
Revenue YoY
17.6%
-6.2%
Net Profit YoY
76.9%
-340.3%
EPS (diluted)
$-0.11
$-1.29

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
GSAT
GSAT
HCAT
HCAT
Q4 25
$72.0M
$74.7M
Q3 25
$73.8M
$76.3M
Q2 25
$67.1M
$80.7M
Q1 25
$60.0M
$79.4M
Q4 24
$61.2M
$79.6M
Q3 24
$72.3M
$76.4M
Q2 24
$60.4M
$75.9M
Q1 24
$56.5M
$74.7M
Net Profit
GSAT
GSAT
HCAT
HCAT
Q4 25
$-11.6M
$-91.0M
Q3 25
$1.1M
$-22.2M
Q2 25
$19.2M
$-41.0M
Q1 25
$-17.3M
$-23.7M
Q4 24
$-50.2M
$-20.7M
Q3 24
$9.9M
$-14.7M
Q2 24
$-9.7M
$-13.5M
Q1 24
$-13.2M
$-20.6M
Gross Margin
GSAT
GSAT
HCAT
HCAT
Q4 25
Q3 25
52.6%
Q2 25
Q1 25
Q4 24
Q3 24
47.5%
Q2 24
Q1 24
Operating Margin
GSAT
GSAT
HCAT
HCAT
Q4 25
-0.5%
-115.3%
Q3 25
13.8%
-22.9%
Q2 25
9.2%
-46.0%
Q1 25
-14.2%
-25.4%
Q4 24
-6.9%
-22.0%
Q3 24
13.0%
-17.9%
Q2 24
-2.4%
-20.8%
Q1 24
-8.3%
-30.5%
Net Margin
GSAT
GSAT
HCAT
HCAT
Q4 25
-16.1%
-121.9%
Q3 25
1.5%
-29.1%
Q2 25
28.6%
-50.8%
Q1 25
-28.9%
-29.9%
Q4 24
-82.1%
-26.0%
Q3 24
13.7%
-19.3%
Q2 24
-16.0%
-17.8%
Q1 24
-23.4%
-27.6%
EPS (diluted)
GSAT
GSAT
HCAT
HCAT
Q4 25
$-0.11
$-1.29
Q3 25
$-0.01
$-0.32
Q2 25
$0.13
$-0.59
Q1 25
$-0.16
$-0.35
Q4 24
$-0.57
$-0.33
Q3 24
$0.00
$-0.24
Q2 24
$-0.01
$-0.23
Q1 24
$-0.01
$-0.35

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
GSAT
GSAT
HCAT
HCAT
Cash + ST InvestmentsLiquidity on hand
$447.5M
$95.7M
Total DebtLower is stronger
$483.8M
$153.3M
Stockholders' EquityBook value
$355.7M
$245.8M
Total Assets
$2.3B
$502.6M
Debt / EquityLower = less leverage
1.36×
0.62×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
GSAT
GSAT
HCAT
HCAT
Q4 25
$447.5M
$95.7M
Q3 25
$346.3M
$91.5M
Q2 25
$308.2M
$97.3M
Q1 25
$241.4M
$342.0M
Q4 24
$391.2M
$392.0M
Q3 24
$51.9M
$387.3M
Q2 24
$64.3M
$308.3M
Q1 24
$59.3M
$327.8M
Total Debt
GSAT
GSAT
HCAT
HCAT
Q4 25
$483.8M
$153.3M
Q3 25
$508.6M
$153.1M
Q2 25
$491.5M
$153.0M
Q1 25
$502.7M
$382.9M
Q4 24
$511.4M
$382.4M
Q3 24
$394.4M
$345.0M
Q2 24
$393.1M
Q1 24
$398.7M
Stockholders' Equity
GSAT
GSAT
HCAT
HCAT
Q4 25
$355.7M
$245.8M
Q3 25
$364.8M
$331.9M
Q2 25
$360.9M
$347.5M
Q1 25
$344.3M
$376.8M
Q4 24
$358.9M
$365.2M
Q3 24
$394.1M
$355.0M
Q2 24
$383.0M
$357.0M
Q1 24
$377.1M
$357.2M
Total Assets
GSAT
GSAT
HCAT
HCAT
Q4 25
$2.3B
$502.6M
Q3 25
$2.2B
$587.1M
Q2 25
$1.9B
$616.2M
Q1 25
$1.7B
$891.5M
Q4 24
$1.7B
$858.9M
Q3 24
$917.6M
$813.0M
Q2 24
$926.2M
$691.7M
Q1 24
$917.0M
$695.1M
Debt / Equity
GSAT
GSAT
HCAT
HCAT
Q4 25
1.36×
0.62×
Q3 25
1.39×
0.46×
Q2 25
1.36×
0.44×
Q1 25
1.46×
1.02×
Q4 24
1.43×
1.05×
Q3 24
1.00×
0.97×
Q2 24
1.03×
Q1 24
1.06×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
GSAT
GSAT
HCAT
HCAT
Operating Cash FlowLast quarter
$175.9M
$9.9M
Free Cash FlowOCF − Capex
$9.6M
FCF MarginFCF / Revenue
12.9%
Capex IntensityCapex / Revenue
0.4%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-697.0K

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
GSAT
GSAT
HCAT
HCAT
Q4 25
$175.9M
$9.9M
Q3 25
$236.0M
$-464.0K
Q2 25
$157.9M
$-9.0M
Q1 25
$51.9M
$280.0K
Q4 24
$340.7M
$-3.5M
Q3 24
$32.0M
$6.2M
Q2 24
$36.7M
$1.6M
Q1 24
$29.8M
$10.3M
Free Cash Flow
GSAT
GSAT
HCAT
HCAT
Q4 25
$9.6M
Q3 25
$-719.0K
Q2 25
$-9.2M
Q1 25
$-390.0K
Q4 24
$-3.9M
Q3 24
$5.5M
Q2 24
$1.3M
Q1 24
$10.1M
FCF Margin
GSAT
GSAT
HCAT
HCAT
Q4 25
12.9%
Q3 25
-0.9%
Q2 25
-11.4%
Q1 25
-0.5%
Q4 24
-4.9%
Q3 24
7.2%
Q2 24
1.7%
Q1 24
13.5%
Capex Intensity
GSAT
GSAT
HCAT
HCAT
Q4 25
0.4%
Q3 25
0.3%
Q2 25
0.3%
Q1 25
0.8%
Q4 24
0.5%
Q3 24
0.9%
Q2 24
0.4%
Q1 24
0.3%
Cash Conversion
GSAT
GSAT
HCAT
HCAT
Q4 25
Q3 25
216.53×
Q2 25
8.22×
Q1 25
Q4 24
Q3 24
3.23×
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

GSAT
GSAT

Services$67.4M94%
Products$4.6M6%

HCAT
HCAT

Recurring Technology$51.9M69%
Professional Services$22.8M31%

Related Comparisons